Federal Food, Drug, and Cosmetic Act

NanoPass and M2N enter strategic development & foundry agreement

Retrieved on: 
Thursday, December 23, 2021
Korea, Federal Food, Drug, and Cosmetic Act, Technology, Silicon, Cosmetics, CE, Time, CEO, Microneedle drug delivery, Growth, MEMS, Skin, Therapy, NES, MD, Trust, Vaccine, FDA, Pharmaceutical industry, Management

YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.

Key Points: 
  • YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.
  • M2N has been an integral and inseparable part of Nanopass's development and manufacturing capabilities since 2007 and has been providing Nanopass with high quality foundry services, ingenuity and quick turn-around on development projects.
  • Kyuho Hwang, CEO of Micro2Nano notes, "M2N has been developing and manufacturing MEMS based microneedles with NanoPass for more than 14 years.
  • Yotam Levin, MD, CEO of NanoPass, added, "M2N has been a trusted partner for over a decade and has been assisting NanoPass regularly with both its development projects and ongoing commercial production.

NanoPass and M2N enter strategic development & foundry agreement

Retrieved on: 
Wednesday, December 22, 2021
Korea, Federal Food, Drug, and Cosmetic Act, Technology, Silicon, Cosmetics, CE, Time, CEO, Microneedle drug delivery, Growth, MEMS, Skin, Therapy, NES, MD, Trust, Vaccine, FDA, Pharmaceutical industry, Management

YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.

Key Points: 
  • YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.
  • M2N has been an integral and inseparable part of Nanopass's development and manufacturing capabilities since 2007 and has been providing Nanopass with high quality foundry services, ingenuity and quick turn-around on development projects.
  • Kyuho Hwang, CEO of Micro2Nano notes, "M2N has been developing and manufacturing MEMS based microneedles with NanoPass for more than 14 years.
  • Yotam Levin, MD, CEO of NanoPass, added, "M2N has been a trusted partner for over a decade and has been assisting NanoPass regularly with both its development projects and ongoing commercial production.

NanoPass and M2N enter strategic development & foundry agreement

Retrieved on: 
Wednesday, December 22, 2021
Korea, Federal Food, Drug, and Cosmetic Act, Technology, Silicon, Cosmetics, CE, Time, CEO, Microneedle drug delivery, Growth, MEMS, Skin, Therapy, NES, MD, Trust, Vaccine, FDA, Pharmaceutical industry, Management

YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.

Key Points: 
  • YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.
  • M2N has been an integral and inseparable part of Nanopass's development and manufacturing capabilities since 2007 and has been providing Nanopass with high quality foundry services, ingenuity and quick turn-around on development projects.
  • Kyuho Hwang, CEO of Micro2Nano notes, "M2N has been developing and manufacturing MEMS based microneedles with NanoPass for more than 14 years.
  • Yotam Levin, MD, CEO of NanoPass, added, "M2N has been a trusted partner for over a decade and has been assisting NanoPass regularly with both its development projects and ongoing commercial production.

NanoPass and M2N enter strategic development & foundry agreement

Retrieved on: 
Wednesday, December 22, 2021
Korea, Federal Food, Drug, and Cosmetic Act, Technology, Silicon, Cosmetics, CE, Time, CEO, Microneedle drug delivery, Growth, MEMS, Skin, Therapy, NES, MD, Trust, Vaccine, FDA, Pharmaceutical industry, Management

YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.

Key Points: 
  • YONGIN-SI, Republic of Korea, and NES ZIONA, Israel, Dec. 22, 2021 /PRNewswire/-- NanoPass Technologies and Micro2Nano (M2N) have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles.
  • M2N has been an integral and inseparable part of Nanopass's development and manufacturing capabilities since 2007 and has been providing Nanopass with high quality foundry services, ingenuity and quick turn-around on development projects.
  • Kyuho Hwang, CEO of Micro2Nano notes, "M2N has been developing and manufacturing MEMS based microneedles with NanoPass for more than 14 years.
  • Yotam Levin, MD, CEO of NanoPass, added, "M2N has been a trusted partner for over a decade and has been assisting NanoPass regularly with both its development projects and ongoing commercial production.

Everly Health Enables Over 45 Million COVID-19 Tests for Americans

Retrieved on: 
Wednesday, December 22, 2021
EVP, Technology, University, Virus, Disease, Cheek, Emergency Use Authorization, Compliance, CEO, Diabetes, Federal Food, Drug, and Cosmetic Act, General manager, Industry, Protein, Founder, Lens, Diagnosis, Organization, Health, COVID-19, PCR, Solution, Lists of television programs, Cancer, COVID, Interest, Safety, Severe acute respiratory syndrome coronavirus 2, Multimedia, Kidney disease, EUA, FDA, Pharmaceutical industry, Vaccine, Natalism

"Through these efforts, I'm proud to share that Everly Health has enabled nearly 45 million COVID tests since the beginning of the pandemic."

Key Points: 
  • "Through these efforts, I'm proud to share that Everly Health has enabled nearly 45 million COVID tests since the beginning of the pandemic."
  • By combining the BD Veritor At-Home COVID-19 Test and associated Scanwell app with Everly Health Solutions' proprietary Lens tool, organizations have the ability to deploy rapid tests and securely view individuals' test results.
  • The digital platform also handles reporting of required data to state and county public health authorities across many test options, including PCR and rapid antigen tests.
  • Everly Health Solutions, a subsidiary of Everly Health, is a virtual care provider that uses advanced diagnostics and telehealth to improve early detection and prevention of disease.

BD Announces New Distribution and Retail Partners for BD Veritor™ At-Home COVID-19 Test

Retrieved on: 
Wednesday, December 22, 2021
Technology, NYSE, Disease, SEG, LinkedIn, Twitter, Federal Food, Drug, and Cosmetic Act, COVID-19, List of life sciences, Human, EUA, Becton, Patient, Compliance, Harveys Supermarkets, Lists of television programs, Element, Amazon (company), COVID, Company, Severe acute respiratory syndrome coronavirus 2, Smartphone, BD, BDX, Becton, Dickinson and Company headquarters, Efficiency, BD (company), Diagnosis, Organization, Health, Therapy, Solution, Safety, Virus, Emergency Use Authorization, Winn-Dixie, Industry, Protein, Government, PCR, School, Southeastern United States, FDA, Grocery store, Animal, Pharmaceutical industry, Natalism, Pharmacy, Southeastern Grocers

We are proud to partner with BD to help protect our communities and stop the spread of the virus."

Key Points: 
  • We are proud to partner with BD to help protect our communities and stop the spread of the virus."
  • The BD Veritor At-Home COVID-19 Test uses the Scanwell mobile app on a smartphone to interpret and provide a digital display of testing results in 15 minutes.
  • The BD Veritor At-Home COVID-19 Test comes with two tests in each box to facilitate serial testing.
  • The BD Veritor At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA).

First-of-its-kind Cue Health Partnership with Air Canada Provides U.S.-based Customers with Special Access to the Most Accurate COVID-19 Self-Test

Retrieved on: 
Tuesday, December 21, 2021
PSAR, Federal Food, Drug, and Cosmetic Act, Travel, National Basketball Association, EUA, CE, School, Entrepreneurship, NBA, FDA, NAAT, Union, Hospital, Health, Trial of the century, Mayo Clinic, Virus, Diagnosis, Emergency Use Authorization, Form, OTC, SAN, Central Drugs Standard Control Organisation, Power-on self-test, MLB, COVID-19, Nursing, Nasdaq, Air Canada Rouge, Partnership, Severe acute respiratory syndrome coronavirus 2, Molisch's test, Hand, Major League Baseball, DTC, National, Prison, Risk, Use, SEC, Interim order, Senior, Multimedia, View, Health Canada, Omicron, Health Sciences Authority, Air Canada, Pharmaceutical industry, Cassette tape, Google, Cue

Under this partnership, each Cue test comes with access to a video proctoring session within the Cue Health App.

Key Points: 
  • Under this partnership, each Cue test comes with access to a video proctoring session within the Cue Health App.
  • "Together with Air Canada, we can now equip U.S. passengers with access to their health information in real-time, providing people with much-needed peace of mind before and after their flights."
  • "Together with Cue Health, we're excited to extend our industry-leading range of testing options that make travelling easier and more predictable.
  • Cue has received Interim Order authorization from Health Canada to sell and distribute its COVID-19 test for both point-of-care and self-testing.

BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing

Retrieved on: 
Tuesday, December 21, 2021
Lists of television programs, Federal Food, Drug, and Cosmetic Act, List of life sciences, Twitter, EUA, COVID-19 testing, Organization, School, FDA, Health, Becton, Infection, Virus, Protein, Diagnosis, Acquisition, LinkedIn, Becton, Dickinson and Company headquarters, Conditional sentence, COVID-19, Efficiency, Safety, BD, Disease, Therapy, Solution, Severe acute respiratory syndrome coronavirus 2, Smartphone, Company, BDX, Patient, Emergency Use Authorization, NYSE, Pharmaceutical industry

"This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future."

Key Points: 
  • "This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future."
  • The Scanwell app is a key differentiator in the market for at-home COVID-19 testing.
  • By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .

SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds OWLT Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

Retrieved on: 
Friday, December 17, 2021
District court, FDA, Federal, Infant, SBG, Bradycardia, Cosmetic, Desaturation, NYSE, Parent, Central District, OWLT, LLP, Fraud, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Marketing, Smart, Federal Food, Drug, and Cosmetic Act, Letter, Oxygen, GLOBE, News, Lead, Private investigator, Architecture, Owlet, Food

Kessler Topaz Meltzer & Check, LLP encourages Owlet investors who have suffered significant losses to contact the firm directly to acquire more information.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP encourages Owlet investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.
  • For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .

Global Pet Supplements Market (2021 to 2027) - Featuring Dechra Pharmaceuticals, Nestle and Zoetis Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Retail, Health, Consumer, Specialty, Pets, Veterinary, People, Mineral, FFDCA, Anxiety, Federal Food, Drug, and Cosmetic Act, Protein, FDA Food Safety Modernization Act, Immunity, PETS, E-commerce, Growth, Food safety, Vitamin, COVID-19, Dog, Adoption, Vaccine, FSMA, Taste, Patient, Hygiene, American Pet Products Association, Longevity, Maintenance, Nutrient, Health, Certification, APPA, Sterilization, Pet, Animal, Bottled water, Pet

The rising expenditure on pet care around the world and the high increment in the adoption of pets are fueling the market growth.

Key Points: 
  • The rising expenditure on pet care around the world and the high increment in the adoption of pets are fueling the market growth.
  • Pet owners are willingly spending a massive amount of money to maintain the health of their pets, leading to higher pet health spending.
  • As per the American Pet Products Association, overall household pet adoption in the US grew significantly in 2016.
  • The players working in the global pet supplement market are witnessing massive growth opportunities due to the booming eCommerce websites.